WEEKLY ANALYSIS REPORT

VOL 1, 2024

WEEKLY INVESTMENT IDEAS

JANUARY 6, 2024

| DATE | STOCK | RECOMD | ENTRY PRICE | TARGET | STOP LOSS |
|----------|--------|--------|-------------|--------|-----------|
| 8.1.2024 | ITC | BUY | 473 | 490 | 460 |
| 8.1.2024 | PNB | BUY | 97 | 106 | 90 |
| 8.1.2024 | ZOMATO | BUY | 133 | 142 | 125 |

NOTE -These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis)


TECHNICAL OUTLOOK

NIFTY WEEKLY CLOSE – 21710.80 (| 20.6 pts)

Last week Nifty began on a positive note and moved higher to a record level of 21834. Nifty did see some profit-booking and closed the week at 21710 with a minor loss of 20 points.

Nifty is placed above all its key averages on daily as well as weekly chart. Daily RSI has moved below its average, while the weekly RSI is placed above its average. Nifty has formed a 'doji' on weekly chart.

Going ahead, Nifty is likely to face resistance near 21800-21850. On the other hand, in case of profitbooking, Nifty is likely to find support near 21500 and 21350.



WEEKLY ANALYSIS REPORT

WEEKLY REVIEW JANUARY 6, 2024

WEEKLY INVESTMENT IDEAS REVIEW

| DATE | STOCK | RECOMD | ENTRY PRICE | TARGET | STOP LOSS | TODAY CLOSE | NET CHANGE (%) | REMARK |
|----------|------------|--------|----------------|--------|--------------|----------------|-------------------|-----------------|
| 1.1.2024 | AUROPHARM | BUY | 1084 | 1125 | 1050 | 1123.95 | 3.55 | Target Achieved |
| 1.1.2024 | JINDALSTEL | BUY | 748 | 775 | 724 | 735.75 | -1.66 | Exit (High 755) |
| 1.1.2024 | GODREJCP | BUY | 1130 | 1165 | 1100 | 1219.85 | 7.37 | Target Achieved |

WEEKLY MARKET REVIEW

Market ends with minor loss

Indian equity indices ended the week on flat note with limited gains. The Nifty settled above the 21,700 level. The broader market sustained its outperformance for second straight week. The upcoming FOMC minutes will provide insight into potential 2024 rate cuts, setting the focus for the week ahead.

In the week ended on Friday, 5 January 2024, the S&P BSE Sensex lost 214.11 points or 0.30% to settle at 72,026.15. The Nifty 50 index shed 20.6 points or 0.09% to settle at 21,710.80. The BSE Mid-Cap index advanced 2.35% to close at 37,706.55. The BSE Small-Cap index rose 2.68% to end at 43,819.39.

Adani Group shares surged after the Supreme Court dismissed the company's petition alleging a conflict of interest against the panel established by the court in March 2023 to investigate claims from the Hindenburg report. Adani Enterprises (up 5.54%), Adani Energy Solutions (up 11.22%), Adani Total Gas (up 10.29%), Adani Green Energy (up 4.8%), Adani Power (up 5.14%), Adani Wilmar (up 6.49%), and Adani Ports and Special Economic Zone (APSEZ) (up 12.69%) advanced.

Dr. Reddy's Laboratories rose 0.84%. The company, through its wholly-owned step-down subsidiary Dr. Reddy's Laboratories, Inc., has acquired 1,014,442 preferred A-1 shares (equivalent to 6.46% stake) of Edity Therapeutics. Edity Therapeuticsis is an Israel based development stage biotechnology company.

Mahindra & Mahindra declined 4.86%. Its overall auto sales for the month of December 2023 stood at 60,188 vehicles, registering a growth of 6.19% as against 56,677 vehicles sold in December 2022.

Eicher Motors fell 6.43%. Its unlisted subsidiary, VE Commercial Vehicles reported 11.1% y-o-y increase in CV sales to 8,026 units in December 2023.

UltraTech Cement tumbled 4.65%. Its consolidated cement sales volume increased 6%YoY to 27.32 million tons in Q3 FY24.

Hero MotoCorp slipped 3.6%. It dispatched 393,952 units of motorcycles and scooters in December 2023.

Sun Pharmaceutical Industries added 3.16%. It has acquired 100% of shares of Libra Merger., a company incorporated in Israel to facilitate consolidation of business in Israel.

Bajaj Auto declined 2.46%. It has sold 3,26,806 units in the month of December 2023, which is higher by 16.08% as compared with 2,81,514 units y-o-y. Meanwhile, the firm informed that its board will mull a share buyback on Monday, 8 January 2024.

IndusInd Bank's stock gained 2.79%. The bank reported a robust 20% y-o-y growth in net advances to Rs 3.26 lakh crore for the quarter ended 31 December 2023. HDFC Bank shed 1.59%. The private lender's gross advances aggregated to approximately Rs 24,69,500 crore as of 31 December 2023, recording a growth of around 62.4% as against Rs 15,20,500 crore as of 31 December 2022.

Grasim Industries added 2.59%. The board of directors approved rights issue of equity shares for an amount aggregating to Rs 3,999.80 crore. The rights issue price is Rs 1,812 per share and record date is 10 January 2024.

Dabur India rose 1.96%. The FMCG major's consolidated revenue is expected to register mid to high single digit growth in Q3 FY24.

Bajaj Finance rallied 5.24%. The NBFC's new loans booked during Q2 FY24 grew by 26% to 8.53 million as compared to 6.76 million in Q2 FY23.

Source: www.capitalmarket.com

WEEKLY ANALYSIS REPORT

SAJAG SECURITIES PVT LTD

SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555 email: business@sajaq.co.in / investorgrievance@sajaq.co.in

NSE TM ID - 07549 BSE TM ID - 3105

NSDL DP ID: IN303647 CDSL DP ID: 12062400

SEBI Regn. No. INZ000221337

Disclosure: This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

Disclaimer: Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based